サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1320059

起立性低血圧治療薬市場：製品タイプ、診断テストタイプ、エンドユーザー別-2023-2030年の世界予測

Orthostatic Hypotension Drugs Market by Product, Diagnostics Test type, End-Use - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 194 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.11円
起立性低血圧治療薬市場：製品タイプ、診断テストタイプ、エンドユーザー別-2023-2030年の世界予測
出版日: 2023年06月12日
発行: 360iResearch
ページ情報: 英文 194 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

起立性低血圧治療薬の世界市場は、2023年に8億7,978万米ドル、CAGR 8.49%と大きく成長し、2030年には15億5,907万米ドルに達すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界の起立性低血圧治療薬市場を評価するために不可欠です。事業戦略や製品満足度などの主要指標を検証することで、ベンダーの包括的な評価を提供し、ユーザーが特定のニーズに基づいて情報に基づいた意思決定を行えるようにします。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.起立性低血圧治療薬の世界市場規模および予測は？

2.予測期間中、世界の起立性低血圧治療薬市場を形成するCOVID-19の阻害要因と影響は？

3.起立性低血圧治療薬の世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？

4.起立性低血圧治療薬の世界市場における競争戦略は？

5.起立性低血圧治療薬の世界市場における技術動向と規制の枠組みは？

6.起立性低血圧治療薬の世界市場における主要ベンダーの市場シェアは？

7.起立性低血圧治療薬の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 起立性低血圧の高リスクに関連する慢性疾患の有病率の増加
      • 高額な医薬品支出と起立性低血圧に対する意識の高まり
      • 複数の大手企業の存在とヘルスケア施設の改善
    • 抑制要因
      • 降圧薬は他の危険因子と重なることが多く、さらなる合併症を増加させます
    • 機会
      • ヘルスケアにおける先進テクノロジーの統合
      • 新薬開発のための大規模な投資と提携
    • 課題
      • ある程度の仰臥位高血圧を誘発しない限り、起立性低血圧の症状を改善することは困難
  • 市場動向
  • COVID-19の累積的な影響
  • ロシア・ウクライナ紛争の累積的影響
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み
  • 顧客のカスタマイズ

第6章 起立性低血圧治療薬市場：製品別

  • ドロキシドパ
  • フルドロコルチゾン
  • インドメタシン
  • 塩酸ミドドリン
  • NSAID
  • ピリドスチグミン

第7章 起立性低血圧治療薬市場診断テストの種類別

  • 血液検査
  • 心電図
  • 心エコー図
  • ストレステスト

第8章 起立性低血圧治療薬市場：最終用途別

  • 外来手術センター
  • クリニック
  • 診断センター
  • 病院

第9章 南北アメリカの起立性低血圧治療薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の起立性低血圧治療薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカの起立性低血圧治療薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ分析：主要企業別

第13章 掲載企業一覧

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. ORTHOSTATIC HYPOTENSION DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, 2022 VS 2030
  • FIGURE 3. ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2022 VS 2030 (%)
  • FIGURE 5. ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2022 VS 2030 (%)
  • FIGURE 6. ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2022 VS 2030 (%)
  • FIGURE 7. ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 8. ORTHOSTATIC HYPOTENSION DRUGS MARKET DYNAMICS
  • FIGURE 9. ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. EUROPE, MIDDLE EAST & AFRICA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. ORTHOSTATIC HYPOTENSION DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 17. ORTHOSTATIC HYPOTENSION DRUGS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. ORTHOSTATIC HYPOTENSION DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 5. ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DROXIDOPA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY FLUDROCORTISONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY INDOMETHACIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY MIDODRINE HYDROCHLORIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY NSAIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PYRIDOSTIGMINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY ECG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY ECHOCARDIOGRAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY STRESS TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 17. ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 148. ORTHOSTATIC HYPOTENSION DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 149. ORTHOSTATIC HYPOTENSION DRUGS MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 150. ORTHOSTATIC HYPOTENSION DRUGS MARKET LICENSE & PRICING
目次
Product Code: MRR-036C5CF3B4D6

The Global Orthostatic Hypotension Drugs Market is forecasted to grow significantly, with a projected USD 879.78 million in 2023 at a CAGR of 8.49% and expected to reach a staggering USD 1,559.07 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Orthostatic Hypotension Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Orthostatic Hypotension Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Product, market is studied across Droxidopa, Fludrocortisone, Indomethacin, Midodrine Hydrochloride, NSAIDs, and Pyridostigmine. The Midodrine Hydrochloride is projected to witness significant market share during forecast period.

Based on Diagnostics Test type, market is studied across Blood Tests, ECG, Echocardiogram, and Stress Test. The Stress Test is projected to witness significant market share during forecast period.

Based on End-Use, market is studied across Ambulatory Surgical Centers, Clinics, Diagnostic Centers, and Hospitals. The Diagnostic Centers is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Orthostatic Hypotension Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Orthostatic Hypotension Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Orthostatic Hypotension Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Orthostatic Hypotension Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Orthostatic Hypotension Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Orthostatic Hypotension Drugs Market?

6. What is the market share of the leading vendors in the Global Orthostatic Hypotension Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Orthostatic Hypotension Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Orthostatic Hypotension Drugs Market, by Product, 2022 vs 2030
  • 4.3. Orthostatic Hypotension Drugs Market, by Diagnostics Test type, 2022 vs 2030
  • 4.4. Orthostatic Hypotension Drugs Market, by End-Use, 2022 vs 2030
  • 4.5. Orthostatic Hypotension Drugs Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growth in the prevalence of chronic diseases associated with high risk of orthostatic hypotension
      • 5.1.1.2. High pharmaceutical expenditure and increased awareness of orthostatic hypotension
      • 5.1.1.3. Presence of several major players and improvement in healthcare facilities
    • 5.1.2. Restraints
      • 5.1.2.1. Hypotensive medications frequently overlap with other risk factors increasing further complications
    • 5.1.3. Opportunities
      • 5.1.3.1. Integration of advanced technologies in healthcare
      • 5.1.3.2. Large investments and collaborations for development of new drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Difficult to improve the symptoms of orthostatic hypotension without inducing some degree of supine hypertension
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Orthostatic Hypotension Drugs Market, by Product

  • 6.1. Introduction
  • 6.2. Droxidopa
  • 6.3. Fludrocortisone
  • 6.4. Indomethacin
  • 6.5. Midodrine Hydrochloride
  • 6.6. NSAIDs
  • 6.7. Pyridostigmine

7. Orthostatic Hypotension Drugs Market, by Diagnostics Test type

  • 7.1. Introduction
  • 7.2. Blood Tests
  • 7.3. ECG
  • 7.4. Echocardiogram
  • 7.5. Stress Test

8. Orthostatic Hypotension Drugs Market, by End-Use

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Clinics
  • 8.4. Diagnostic Centers
  • 8.5. Hospitals

9. Americas Orthostatic Hypotension Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Orthostatic Hypotension Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Orthostatic Hypotension Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing